tbuckley/cabot-search huggingface dataset:
Adenosine and Cardioprotection in the Diseased Heart
Authors: Masafumi Kitakaze, Tetsuo Minamino, Koichi Node, Seiji Takashima, Hiroharu Funaya, Tsunehiko Kuzuya, Masatsugu Hori
Journal: Circulation (1999)

Biological and mechanical stressors such as ischemia, hypoxia, cellular ATP depletion, Ca2+ overload, free radicals, pressure and volume overload, catecholamines, cytokines, and renin-angiotensin may independently cause reversible and/or irreversible cardiac dysfunction. As a defense against these forms of stress, several endogenous self-protective mechanisms are exerted to avoid cellular injury. Adenosine, a degradative substance of ATP, may act as an endogenous cardioprotective substance in pathophysiological conditions of the heart, such as myocardial ischemia and chronic heart failure. For example, when brief periods of myocardial ischemia precede sustained ischemia, infarct size is markedly limited, a phenomenon known as ischemic preconditioning. We found that ischemic preconditioning activates the enzyme responsible for adenosine release, ie, ecto-5'-nucleotidase. Furthermore, the inhibitor of ecto-5'-nucleotidase reduced the infarct size-limiting effect of ischemic preconditioning, which establishes the cause-effect relationship between activation of ecto-5'-nucleotidase and the infarct size-limiting effect. We also found that protein kinase C is responsible for the activation of ecto-5'-nucleotidase. Protein kinase C phosphorylated the serine and threonine residues of ecto-5'-nucleotidase. Therefore, we suggest that adenosine produced via ecto-5'-nucleotidase gives cardioprotection against ischemia and reperfusion injury. Also, we found that plasma adenosine levels are increased in patients with chronic heart failure. Ecto-5'-nucleotidase activity increased in the blood and the myocardium in patients with chronic heart failure, which may explain the increases in adenosine levels in the plasma and the myocardium. In addition, we found that further elevation of plasma adenosine levels due to either dipyridamole or dilazep reduces the severity of chronic heart failure. Thus, we suggest that endogenous adenosine is also beneficial in chronic heart failure. We propose potential mechanisms for cardioprotection attributable to adenosine in pathophysiological states in heart diseases. The establishment of adenosine therapy may be useful for the treatment of either ischemic heart diseases or chronic heart failure.
Myeloablative Bone Marrow Transplantation in Young Adults with Sickle Cell Disease: the French Experience
Authors: Mathieu Kuentz, Marie Robin, Nathalie Dhedin, Cécile Pautas, Regis Peffaut De La Tour, Pierre Rohrlich, Pierre Bordigoni, Gérard Socié, Catherine Cordonnier, Francoise Bernaudin
Journal: Blood (2010)
An Increased Frequency of Abnormalities Including Uniparental Disomy Is Detected by SNP Array Compared with Conventional Karyotype Analysis in Acute Myeloid Leukemia.
Authors: Manoj Raghavan, Rosemary E. Gale, Spyros Skoulakis, Tracy Chaplin, Gael Y. Molloy, David C. Linch, Alan K. Burnett, Bryan D. Young
Journal: Blood (2005)
P3.07-003 Effectiveness of Pemetrexed in Advanced Non-Squamous NSCLC and Estimation of Its Impact on Public Health in France
Authors: Mickael Basson, Ghassan Sleilaty, Kaisa-Leena Taipale, Mark Boye, Katherine Bellebaum Winfree, James Eaton, Rachel Evans, Christos Chouaid
Journal: Journal of Thoracic Oncology (2017)
MA02.03 Expression of Oncofetal miRNAs Inactivates NFIB, a Developmental Transcription Factor Linked to Tumor Aggressiveness in Lung Adenocarcinoma
Authors: Daiana Becker-Santos, Brenda Minatel, Kim Lonergan, Kelsie Thu, John English, Victor Martinez, Calum Macaulay, William Lockwood, Wendy Robinson, Igor Jurisica, Stephen Lam, Wan Lam
Journal: Journal of Thoracic Oncology (2017)
Pattern of surrogate decision-making in Korean patients with cancer.
Authors: J. K. Lee, B. Keam, A. R. An, T. M. Kim, S. Lee, D. Kim, D. S. Heo
Journal: Journal of Clinical Oncology (2011)

e19554 Background: Even though patient self-determination is encouraged, clinical decisions involving cancer patients are often made by surrogates, but sometimes their judgment conflicts with the will of the patient. The goal of this study was to evaluate the pattern of such decisions by proxy and investigate scenarios of surrogate consent. Methods: A single-center, retrospective study of cancer patients, who expired between Jan 1, 2009 and Dec 31, 2009 was conducted at Seoul National University Hospital, Seoul, Korea. Informed consents (N= 8,639) from 575 cancer patients were reviewed. The documents incorporated do-not-resuscitate (DNR) directives, intensive care unit (ICU) admission, emergency hemodialysis, interventional/ diagnostic procedures, chemotherapy, and radiotherapy. Patient records were examined for time of signature and status of those granting consent. Variables impacting surrogate decisions were analyzed via multiple logistic regression. Results: Of the 8,639 consent forms, 3,481 (40.3%) were signed by surrogates. Surrogate involvement was more likely, if patient death was imminent (survival > 1 yr: reference; survival 1 to 12 mo: adjusted odds ratio [aOR]=2.273, P<0.001; survival < 1 mo: aOR=13.209, P<0.001). Surrogates were also more frequently implicated in DNR, ICU admission, emergency hemodialysis, and invasive intervention, as opposed to chemotherapy, radiotherapy, and noninvasive diagnostics (aOR=3.881, P<0.001). Conclusions: Surrogate decision-making is a common accompaniment of cancer management in Korea. The rate increases significantly with end-of-life care, when patient death is imminent.
Abnormal Large Platelets Are Associated Not Only with von Willebrand Disease (VWD) Type 2B (Including Type 2B/1 New York) but Also with Severe Type 3: A Potential Role for von Willebrand Factor (VWF) in Megakaryocytopoiesis.
Authors: Paquita Nurden, Alan T. Nurden, Jocelyne Enouf, Silvia La Marca, Luciano Baronciani, Augusto B. Federici
Journal: Blood (2007)
QUANTITATIVE EVALUATION OF THE ST-T PATTERN IN THE EXERCISE ELECTROCARDIOGRAM
Authors: Masakatsu Fukushima
Journal: Circulation (1977)

A new method for the quantitative analysis of the exercise electrocardiogram was developed for the diagnosis of coronary heart disease. In this method, a second order function, f(t)=at2+bt +c, which represents the configuration of the initial portion of the ST-T segment was obtained by the function fitting method and its coefficients a (a parameter which represents the ST-T pattern) and c (a parameter which reflects the ST junction's depression) were used for the evaluation of the exercise electrocardiogram. Serial changes in the ST-T pattern throughout exercise tests were also investigated using this method in two distinct groups; a group of 35 healthy adults (group H) and a group of 28 patients with effort angina pectris (group EA). Although the smaller coefficients a and c which were obtained during an after exercise tests in group EA may reflect the ischemic changes, substantially large overlaps in each of these parameters was observed between group H and group EA. However, the discrimination between these two groups was improved if the combination of coefficients a and c were applied. These results strongly suggest that the configuration of the ST-T pattern is indispensable for the evaluation of the exercise electrocardiogram and that the new quantitative method used in this study is useful in the objective analysis of the fine changes in the ST-T pattern.
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
Authors: Phoenix A. Ho, Rong Zeng, Todd A. Alonzo, Robert B. Gerbing, Kristen L. Miller, Jessica A. Pollard, Derek L. Stirewalt, Nyla A. Heerema, Susana C. Raimondi, Betsy Hirsch, Janet L. Franklin, Beverly Lange, Soheil Meshinchi
Journal: Blood (2010)
Effect of Iron Levels on Women After Premature or Early-Onset Menopause
Authors: Luca Mascitelli, Mark R. Goldstein
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Peripheral Blood Involvement with Minimal Disease Is Common in Multiple Myeloma but Not in Smoldering Myeloma
Authors: Prashant Ramesh Tembhare, Constance Yuan, Neha Korde, Elisabet E. Manasanch, Mary Kwok, Mark Roschewski, Irina Maric, Katherine R Calvo, Marcia Mulquin, Diamond Zuchlinski, Ola Landgren, Maryalice Stetler-Stevenson
Journal: Blood (2012)
P2.03a-006 Frequency of 2 Year PFS Milestone in Stage IV NSCLC Patients Treated with First Line Pemetrexed/Platinum and Pemetrexed Maintenance
Authors: Jason Macklis, Fatima Saleem, Fatema Esmail, Sanjib Basu, Mary Fidler, Philip Bonomi, Marta Batus
Journal: Journal of Thoracic Oncology (2017)
Experts argue over benefits of diet drinks
Authors: Jacqui Wise
Journal: BMJ (2017)

A row has blown up around the benefits of sugar-free or “diet” drinks after academics claimed, in the open access journal PLoS Medicine , that these are no more helpful than the full sugar versions for maintaining a healthy weight.1 However, other experts have criticised their conclusions and fear that they may add to public confusion.

Academics from Imperial College London and two universities in Brazil wrote in a commentary article that, although artificially sweetened beverages may be perceived by consumers as the healthier option, no solid evidence supports the claims that they are healthier or can help prevent obesity and diseases such as type 2 diabetes.

They emphasised concerns that artificially sweetened beverages may trigger compensatory …
A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors.
Authors: S. A. Ghamande, C. Lin, D. C. Cho, T. A. Coleman, I. Chaudhary, J. M. Cleary, M. H. Silverman, M. Kuo, W. Mach, Y. Tseng, S. C. Hsu, S. Goel
Journal: Journal of Clinical Oncology (2011)

e13618 Background: The phase I first-in-human study of TLC388 (Lipotecan) examined the MTD, safety, anti-tumor activity and pharmacokinetic profiles in patients with advanced incurable solid tumors. Methods: Lipotecan was administered intravenously on day 1, 8 and 15 of a 28-day cycle. Patients underwent tumor assessments every other cycle. Pharmacokinetic samples were drawn on days 1, 8 and 15 of cycles 1 and 2. Results: Fifty four previously treated patients with advanced or metastatic solid tumors were enrolled The dose was escalated from 1.5 mg/m2 to 60 mg/m2 over 12 patient cohorts. MTD was reached at 50 mg/m2. DLTs above that dose were thrombocytopenia and febrile neutropenia. Treatment was well-tolerated and no accumulated toxicity seen. Treatment related G3/4 hematological toxicity include neutropenia (19%), leucopenia (15%), anemia (9%), and thrombocytopenia (7%). G3/4 non-hematological side effects were diarrhea (2%) and hyponatremia (4%). Twenty one of 35 evaluable patients (60%) continued therapy beyond cycle 2, received a median of 4.5 cycles (2-12 cycles), and had stable disease or minor tumor regression. Prolonged (≥ 6 months) stable disease was noted in 8 patients (23%), including renal (chromophobe and clear cell types), docetaxel refractory prostate, salivary gland, sorafenib refractory hepatic, and vaginal cancers. One minor response occurred in a heavily pretreated 70-year-old male with stage II B thymoma cancer metastatic to lung, liver and lymph nodes who was treated for 12 courses and remains on the study. PET-CT scan revealed tumor size reduction of 22% at cycle 10. Pharmacokinetics of TLC388 was dose-independent; mean (SD) values for the volume of distribution at steady-state and clearance were 857 (1122) L/m2 for S,R-TLC388 and 996 (1333) L/m2 for S,S-TLC388, and 2174 (2526) L/h-m2 for S,R-TLC388 and 2670 (2988) L/h-m2 for S,S-TLC388, respectively. The half-life values averaged 0.67 (1.15) hours for S,R-TLC388 and 0.64 (1.11) hours for S,S-TLC388. Conclusions: Lipotecan at dose of 50 mg/m2 on current treatment schedule is safe, well tolerated, and demonstrates broad antitumor activity to support phase II disease-specific investigations.
P2.02-020 Pattern of Care of Inoperable Locally Advanced (LA) NSCLC in Elderly Patients: Analysis of the Experience of Two Academic Italian Hospitals
Authors: Marco Perna, Vieri Scotti, Alessio Bruni, Gabriele Simontacchi, Vanessa Di Cataldo, Emanuela Olmetto, Giulio Alberto Carta, Roberta Grassi, Carlotta Becherini, Carla De Luca Cardillo, Benedetta Agresti, Camilla Comin, Katia Ferrari, Elisa D'Angelo, Polina Vasilyeva, Bruno Meduri, Frank Lohr, Luca Voltolini, Lorenzo Livi
Journal: Journal of Thoracic Oncology (2017)
P1.01-037 Baseline Demographics and Comorbidities of Patients with Advanced NSCLC Compared to the General Population from Two Regions in Sweden
Authors: Stephan Linden, Ana Banos Hernaez, Josefine Reding, Jonas Nilsson, Nahila Justo, Jukka Montonen, Patrice Verpillat
Journal: Journal of Thoracic Oncology (2017)
Frequent Mutations and Their Influence on Prognosis in Patients with Acute Myeloid Leukemia
Authors: Ekaterina Petrova, Irina Martynkevich, Luybov Polushkina, Luydmila Martynenko, Marina Ivanova, Natalia Cybakova, Elizaveta Kleina, Elena Shabanova, Alexandr Chechetkin, Vasily Shuvaev, Kudrat Abdulkadirov
Journal: Blood (2015)
S70 Neonatal airway epithelial cell IL-8 responses to infection are reduced in those who go on to wheeze
Authors: SW Turner, D Miller, G Walsh, U Power, M Shields, G Devereux
Journal: Thorax (2016)

<h3>Introduction</h3> Airway epithelial cells (AEC) are important contributors to the innate immune system and AEC function in children with asthma differs to that of children without asthma. We recruited a birth cohort to establish whether AEC function was abnormal before the onset of asthma symptoms. <h3>Methods</h3> Pregnant mothers were recruited and nasal AEC brushings were collected from neonates within 48 hours of birth. Cells were cultured in a submerged model and stimulated with tumour necrosis factor alpha/interleukin-1 beta (TNFa/IL1b), lipopolysaccharide (LPS) and house dust mite (HDM). The mediators in the culture supernatant were quantified by cytometric bead array or ELISA and included: interleukin (IL)−6, IL-8, granulocyte macrophage colony stimulating factor (GMCSF) and interferon gamma (IFNg). The primary outcome of interest was IL-8 expressed as median [interquartile range] in pg/mg protein. Parents returned a postal questionnaire when their child was four years old. <h3>Results</h3> AEC were successfully cultured in 139 neonates of whom 120 were contacted and 85 questionnaires were returned. The mean age was 3.8 years, 42 were boys and 10 reported wheeze in the previous 12 months. Neonates who had recent wheeze at four years had reduced median AEC IL-8 release after exposure to TNFa/IL1b (60 [33, 71] versus 105 [64, 157], p = 0.002, see Figure 1) or to LPS (2.2 [0, 9.0] versus 10.5 [4.6, 24.0] p = 0.038) compared to those who did not wheeze. Neonatal AEC GMCSF release was also reduced after exposure to TNFa/IL1b in those who later wheezed compared to non wheezers (0.09 [0.01, 0.72] versus 0.67 [0.32, 1.48] p = 0.014). Neonatal AEC release of IFNg and IL-6 were not associated with later wheeze. Maternal asthma was not associated with AEC IL-8 release. <h3>Conclusions</h3> These results suggest that an abnormality which is present at birth in AEC response to infection is important to asthma causation.
Functional lipidomics: Palmitic acid impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose metabolism
Authors: Ling Lin, Ying Ding, Yi Wang, Zhenxin Wang, Xuefei Yin, Guoquan Yan, Lei Zhang, Pengyuan Yang, Huali Shen
Journal: Hepatology (2017)

Lipids are essential cellular components and energy sources of living organisms, and altered lipid composition is increasingly recognized as a signature of cancer. We performed lipidomic analysis in a series of hepatocellular carcinoma (HCC) cells and identified over 1,700 intact lipids originating from three major lipid categories. Comparative lipidomic screening revealed that 93 significantly changed lipids and decreased palmitic acyl (C16:0)–containing glycerophospholipids were positively associated with metastatic abilities of HCC cells. Furthermore, both in vitro and in vivo experiments demonstrated that C16:0 incubation specifically reduced malignant cell proliferation, impaired cell invasiveness, and suppressed tumor growth in mouse xenograft models. Biochemical experiments demonstrated that C16:0 treatment decreased cell membrane fluidity and limited glucose metabolism. A phosphoproteomics approach further revealed such C16:0 incubation attenuated phosphorylation levels of mammalian target of rapamycin (mTOR) and signal transducer and activator of transcription 3 (STAT3) pathway proteins. Multiple reaction monitoring analysis of 443 lipid molecules showed 8 reduced C16:0‐containing lipids out of total 10 altered lipids when cancer tissues were compared with adjacent nontumor tissues in a cohort of clinical HCC specimens ( P &lt; 0.05). Conclusion : These data collectively demonstrate the biomedical potential of using altered lipid metabolism as a diagnostic marker for cancerous cells and open an opportunity for treating aggressive HCCs by targeting altered C16:0 metabolism. (H epatology 2017;66:432–448).
P3.03-032 PET/CT for Patients with Very Early Clinical Stage of Malignant Pleural Mesothelioma: When Can PET/CT Detect Tumor Growth of T0/T1a Mesothelioma?
Authors: Yoshiki Negi, Kozo Kuribayashi, Eriko Fujimoto, Yuichi Koda, Shingo Kanemura, Eisuke Shibata, Taiichiro Otsuki, Koji Mikami, Takashi Nakano
Journal: Journal of Thoracic Oncology (2017)
c-Myc Amplification in Non Hodgkin’s-Lymphomas with Burkitt-Like Features Is Associated with a Poor Prognosis.
Authors: Hossein Mossafa, Diane Damotte, Anne Vincenneau, Isabelle Amouroux, Nareth Athken, Arache Djnabian, Roland Jeandel, Eli Khoury, Jean-Michel Martelli, Thierry Samson, Sylvie Tapia, Georges Flandrin, Xavier Troussard
Journal: Blood (2004)
Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies
Authors: Tim Illidge, Andrei Ivanov, Stephen A Beers, Claire Walshe, Claude Chan, Waleed Alduaij, Martin J. Glennie, Mark S Cragg
Journal: Blood (2008)
P1.03-068 Impact of Positive Pleural Lavage Cytology or Malignant Effusion on Survival in Patients Having Lung Resection for NSCLC
Authors: Tomohiro Obata, Naoya Yamasaki, Yuka Kitamura, Go Hatachi, Takuro Miyazaki, Keitaro Matsumoto, Tomoshi Tsuchiya, Kazuhiro Tabata, Takeshi Nagayasu
Journal: Journal of Thoracic Oncology (2017)
Increased p53 Acetylation By SIRT1 Inhibition Is Required for Optimal Activation of p53 Activity and Significantly Enhances the Ability of HDM2 Inhibitors to Target CML LSC
Authors: Yann Pierre Kevin Duchartre, Ling Li, Tinisha McDonald, YinWei Ho, Yao-Te Hsieh, Ravi Bhatia
Journal: Blood (2014)
Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics.
Authors: John D. Shaughnessy, Jeffrey Haessler, Ichiro Hanamura, Yongsheng Huang, James P. Stewart, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie
Journal: Blood (2006)
Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort
Authors: Z Ez-Zaitouni, P A C Bakker, M van Lunteren, I J Berg, R Landewé, M van Oosterhout, M Lorenzin, D van der Heijde, F A van Gaalen
Journal: Annals of the Rheumatic Diseases (2017)

Concerns have been raised about overdiagnosis of axial spondyloarthritis (axSpA). We investigated whether patients with chronic back pain (CBP) of short duration and multiple SpA features are always diagnosed with axSpA by the rheumatologist, and to what extent fulfilment of the Assessment of SpondyloArthritis International Society (ASAS) axSpA criteria is associated with an axSpA diagnosis.Baseline data from 500 patients from the SPondyloArthritis Caught Early cohort which includes patients with CBP (≥3 months, ≤2 years, onset <45 years) were analysed. All patients underwent full diagnostic workup including MRI of the sacroiliac joints (MRI-SI) and radiograph of sacroiliac joints (X-SI). For each patient, the total number of SpA features excluding sacroiliac imaging and human leucocyte antigen B27 (HLA-B27) status was calculated.Before sacroiliac imaging and HLA-B27 testing, 32% of patients had ≤1 SpA feature, 29% had 2 SpA features, 16% had 3 SpA features and 24% had ≥4 SpA features. A diagnosis of axSpA was made in 250 (50%) of the patients: 24% with ≤1 SpA feature, 43% with 2 SpA features, 62% with 3 SpA features and 85% with ≥4 SpA features. Of the 230 patients with a positive ASAS classification 40 (17.4%) did not have a diagnosis of axSpA. HLA-B27 positivity (OR 5.6; 95% CI 3.7 to 8.3) and any (MRI-SI and/or X-SI) positive imaging (OR 34.3; 95% CI 17.3 to 67.7) were strong determinants of an axSpA diagnosis.In this cohort of patients with CBP, neither the presence of numerous SpA features nor fulfilment of the ASAS classification criteria did automatically lead to a diagnosis axSpA. Positive imaging was considered particularly important in making a diagnosis of axSpA.
A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Authors: Elizabeth A. Griffiths, William Brady, Wei Tan, Carlos E Vigil, James E. Thompson, Laurie A Ford, Noelle M Dickey, Jill Sperrazza, Eunice S. Wang, Meir Wetzler
Journal: Blood (2014)
Curcumin Down-Regulates Cytokine-Mediated Tissue Factor and Plasminogen Activator Type 1 Expression In Human Endothelial Cells
Authors: Eriko Morishita, Keiko Maruyama, Hidesaku Asakura, Shigeki Ohtake, Akihiro Yachie, Shinji Nakao
Journal: Blood (2010)